SENATE RESOLUTION NO. 28  
BY SENATOR FESI

A RESOLUTION

To urge and request the Louisiana Department of Health to report on the use and results of hydroxychloroquine for treating Medicaid recipients relative to COVID-19.

WHEREAS, hydroxychloroquine, also known as hydroxychloroquine sulfate, was approved for medical use in the United States in 1955; and

WHEREAS, hydroxychloroquine is used to treat rheumatoid arthritis and lupus, and can be used to prevent malaria; and

WHEREAS, hydroxychloroquine has been proposed as a treatment for COVID-19 and has been the focus of several randomized, double-blind, placebo-controlled trials across the United States and parts of Canada; and

WHEREAS, according to the Louisiana Department of Health, as of October 19, 2020, there have been 2,594,376 COVID-19 tests administered; 175,982 confirmed COVID-19 diagnoses; and 5,566 confirmed COVID-19 deaths in Louisiana; and

WHEREAS, more than 1.8 million Louisianians are enrolled in the state Medicaid program; and

WHEREAS, Medicaid recipients' services covered and outcomes achieved are reliable and readily available data sets that can be used to determine the use and results of hydroxychloroquine.

THEREFORE, BE IT RESOLVED that the Senate of the Legislature of Louisiana does hereby request the Louisiana Department of Health to report on the use and results of hydroxychloroquine for treating Medicaid recipients relative to COVID-19.

BE IT FURTHER RESOLVED that the department shall report the following information for the control period of March 2020 through October 2020:

(1) The number of Medicaid recipients who were taking hydroxychloroquine for rheumatoid arthritis, lupus, or to prevent malaria during the control period and tested positive for COVID-19.
(a) Of those recipients who tested positive for COVID-19, how many were hospitalized and what was the duration of the hospitalization.

(b) Of those recipients who tested positive for COVID-19, how many deaths occurred whether hospitalized or not.

(2) The number of Medicaid recipients who were not taking hydroxychloroquine for rheumatoid arthritis or lupus, or to prevent malaria during the control period, tested positive for COVID-19, and were treated with hydroxychloroquine as a COVID-19 post-exposure prophylaxis.

(a) Of those recipients treated with hydroxychloroquine as a COVID-19 post-exposure prophylaxis, how many were hospitalized and what was the duration of the hospitalization.

(b) Of those recipients treated with hydroxychloroquine as a COVID-19 post-exposure prophylaxis, how many deaths occurred whether hospitalized or not.

BE IT FURTHER RESOLVED that, to comply with the reporting requirement of this Resolution, the department may consult and receive assistance from a state academic institution.

BE IT FURTHER RESOLVED that the department shall submit a data report to the Senate no later than August 1, 2021.

BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the secretary of the Louisiana Department of Health.

PRESIDENT OF THE SENATE